GlassScriptPhysician profile
Kera Walter
NPI 1689049652
$2,855.76
in general payments reported to CMS, 2019-2025
26 companies · $400 in 2025
The $400 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $470 · 2020: $18.22 · 2021: $39.28 · 2022: $393 · 2023: $883 · 2024: $652 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,935.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,935.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,050.80 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $245.20 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $228.52 | 2019-2024 | |
| Lilly USA, LLC | $219.10 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Medtronic, INC. | $169.68 | 2024 | Minimed 780g |
| Glaxosmithkline, LLC. | $140.82 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $132.02 | 2019-2025 | Otezla, Repatha, Repatha |
| Exact Sciences Corporation | $122.87 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $95.26 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Astellas Pharma US INC | $60.59 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $49.83 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.26 | 2019 | |
| Biogen, INC. | $34.22 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.31 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.33 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $28.78 | 2019 | |
| Ethicon INC. | $23.87 | 2024 | Monarch Platform |
| Abbott Laboratories | $23.54 | 2025 | Freestyle Libre 3 |
| Supernus Pharmaceuticals, INC. | $22.14 | 2023 | Qelbree |
| Gilead Sciences, INC. | $20.59 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $18.89 | 2025 | Rexulti |
| Seqirus USA INC | $15.95 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.88 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.90 | 2025 | |
| Sanofi-Aventis U.S. LLC | $12.42 | 2019 | |
| Amarin Pharma, INC. | $11.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kera Walter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.